Evolving Approaches to Intensive Insulin Therapy in Type 1 Diabetes: Multiple Daily Injections, Insulin Pumps and New Methods of Monitoring

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 4, 2003, Pages 325-334

  Stephens, Elizabeth ^a   Riddle, Matthew ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Basal bolus therapy; Continuous subcutaneous insulin infusion; Intensive insulin therapy; Multiple daily injections

Indexed keywords

AMYLIN; GLUCAGON; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PRAMLINTIDE;

BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DRUG COST; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN TREATMENT; META ANALYSIS; REVIEW; SIDE EFFECT; SYRINGE; WEIGHT GAIN;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; HUMANS; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN, ISOPHANE;

EID: 0345169029     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027345927676     Document Type: Review

References (53)

1. DCCT Treatment Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:977-986.
2. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003;289:2254-2264.
3. The Writing Team for the DCCT/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
4. Hirsch IB. Intensive treatment of type 1 diabetes. Medical Clinics of North America 1998;82:689-719.
5. Stephens E, Ryan-Turek T. Intensive Insulin Therapy, Endocrine Secrets. Hanley & Belfus, Inc., Publishers, 2002.
6. The DCCT Research Group. Effect of intensive insulin therapy on residual β-cell function in patients with type 1 diabetes in the DCCT: A randomized, controlled trial. Ann Intern Med 1998;128:517-523.
7. Chantelau E, Schiffers T, Schutze J, Hanser B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Education and Counseling 1997;30:167-173.
8. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ 2002;325:746-751.
9. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complication trial. Am J Med 1991;90:450-459.
10. Boyle PJ. Hypoglycemia in The Medical Management of Diabetes Mellitus. New York: Marcel Dekker, Inc., 2000:527-538.
11. Chantelau E, Kohner EM. Why some cases of retinopathy worsen when diabetic control improves. BMJ 1997;315:1105-1106.
12. Fanelli CG, Pampenelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB. Administration of neutral protamine Hagedorn insulin at bed-time versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. Ann Intern Med 2002;136:504-514.
13. Scholtz HE, van Niekert, Meyer BH, Rosenkranz B. As assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycemic clamp technique. Diabetologica 1998;47 (Supp 1):A235.
14. Tunbridge FK, Newens A, Home PD, Davie SN, Murphy M, Burrin JM, Alberti KG, Jensen I. A comparison of human ultralente- and lente-based twice-daily injection regimens. Diab Med 1989;6:496-501.
15. Anderson JH Jr, Brunell RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-270.
16. Home PD, Lindholm A, Hylleberg B, Round P, for the UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998;21:1904-1909.
17. Levien TL, Baker DE, White JR Jr, Campbell RK. Insulin glargine: A new basal insulin. Ann Pharmacother 2002;36:1019-1027.
18. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA for the U.S. Study Group of Insulin Glargine in type 1 diabetes: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643.
19. Raskin P, Halle J-P, Klaff L, Donley D, Bergenstal R, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-1671.
20. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donely DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE901) and NPH insulin. Diabetes Care 2001;24:631-636.
21. Younis N, Soran H, Boen-Jones D. Insulin glargine: A new basal insulin analogue. Q J Med 2002;95:757-761.
22. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtimes. Diabetes Care 2003;26:1490-1496.
23. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes, clinical applications. JAMA 2003;289:2265-2269.
24. Kelly JL, Trence DL, Hirsch IB. Rapid decrease in clinically significant hypoglycemia with insulin glargine. Diabetes 2002;51:A123.
25. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtimes. Diabetes Care 1999;22:468-477.
26. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22:137-140.
27. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes Management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18(Supp 1):S14-S20.
28. Pickup JM, Mattock M, Kerry S. Glycemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomized controlled trials. BMJ 2002;324:1705-1708.
29. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: A meta-analysis. Diabetes Care 2003;26:1079-1087.
30. Scholtz HE, van Hiekerk N, Meyer BH, Rosenkranz B. An assessment of the variability in the pharmacodynamics (glucose lowering effect of HOE901 compared to NPH and ultralente human insulins using the euglycemic clamp technique. Diabetologica 1999;42(Suppl 1):882.
31. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996;19:324-327.
32. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Diabetes Care 2002;25:593-598.
33. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-376.
34. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial monitoring in women with gestational diabetes mellitus requiring insulin therapy. NEJM 1995;333:1237-1241.
35. American Diabetes Association. Tests of Glycemia in Diabetes. Diabetes Care 2003;26:S 106-S 108.
36. US Food and Drug Administration. Therasense, Inc. FreeStyle Tracker™ Diabetes Management System. www.fda.gov 2002.
37. Jungheim K, Kischinsky T. Risky delay of hypoglycemia detection in glucose monitoring at the arm. Diabetes Care 2001;24:1303-1304,
38. Jungheim K, Koschinsky T. Glucose monitoring in the arm. Risky delays of hypoglycemia and hyperglycemia detection. Diabetes Care 2002;25:956-960.
39. Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM. Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care 2003;26:981-985.
40. Peled N, Letter to the Editor. Timely detection of hypoglycemia by monitoring blood glucose levels of samples obtained from the palm of the hand. Diabetes Tech Therap 2002;4:83-85.
41. U.S. Food and Drug Administration, Center for Devices and Radiologic Help. Glucose meters and Diabetes Management: http://www.fda.gov/diabetes/glucose.html#12, updated 5/1/02.
42. Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002;25:1185-1191.
43. Monsod TP, Flanagan DE, Rife F, Sainz R, Caprio S, Sherwin RS, Tamborlane WV. Do sensor glucose levels accurately predict plasma glucose concentrations dduring hypoglycemia and hyperinsulinemia? Diabetes Care 2002;25:889-893.
44. McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 2002;25:1499-1503.
45. Bode BW, Gross TM, Thomton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: A pilot study. Diabetes Research and Clinical Practice 1999;46:183-190.
46. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with typel diabetes. Pediatrics 2001;107:222-226.
47. Boullu-Sanchis S, Jeandidier N, Meyer L, Busch M-S, Ott F, Pinget M. Use of continuous glucose monitoring system (CGMS) in 23 insulin treated diabetic patients: Feasibility, reliability and efficacy for the diagnosis of unnoticed hypoglycemia (glycemia ≤ mmol/l) Diabetes 2001;50(Suppl 2):A447.
48. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO, Cygnus Research Team. Noninvasive glucose monitoring: Comprehensive clinical results. JAMA 1999;282:1839-1844.
49. Chase PH, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman RC. Use of the Glucowatch Biographer in children with type 1 diabetes. Pediatrics 2003;111:790-794.
50. GlucoWatch G2 Product Insert, Sankyo, Cygnus, 2002.
51. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second β-cell hormone. Diab Tech & Ther 2002;4:175-189.
52. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-730.
53. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003;26:1-8.